Jeremy Grantham's REGN Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 61,474 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $34.56 M, representing 0.10% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2020, adding 27,700 shares. Largest reduction occurred in Q1 2019, reducing 30,100 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +30,601 | Add 0.00% | 30,600 | $224.87 |
| Q3 2013 | -30,600 | Sold Out | 30,600 | $0.00 |
| Q1 2019 | +500 | New Buy | 500 | $410.00 |
| Q2 2019 | +10,600 | Add 2120.00% | 11,100 | $312.97 |
| Q3 2019 | -11,100 | Sold Out | 11,100 | $0.00 |
| Q2 2020 | +456 | New Buy | 456 | $622.81 |
| Q4 2020 | +27,700 | Add 6074.56% | 28,156 | $483.09 |
| Q1 2021 | +13,444 | Add 47.75% | 41,600 | $473.15 |
| Q2 2021 | +6,900 | Add 16.59% | 48,500 | $558.54 |
| Q3 2021 | +800 | Add 1.65% | 49,300 | $605.17 |
| Q4 2021 | -1,900 | Reduce 3.85% | 47,400 | $631.52 |
| Q1 2022 | +500 | Add 1.05% | 47,900 | $698.41 |
| Q2 2022 | +8,500 | Add 17.75% | 56,400 | $591.13 |
| Q3 2022 | -2,400 | Reduce 4.26% | 54,000 | $688.87 |
| Q4 2022 | +17,142 | Add 31.74% | 71,142 | $721.49 |
| Q1 2023 | -4,000 | Reduce 5.62% | 67,142 | $821.67 |
| Q2 2023 | -14,238 | Reduce 21.21% | 52,904 | $718.54 |
| Q3 2023 | +5,036 | Add 9.52% | 57,940 | $822.96 |
| Q4 2023 | +9,160 | Add 15.81% | 67,100 | $878.29 |
| Q1 2024 | -9,240 | Reduce 13.77% | 57,860 | $962.49 |
| Q2 2024 | -596 | Reduce 1.03% | 57,264 | $1051.03 |
| Q3 2024 | -5,267 | Reduce 9.20% | 51,997 | $1051.24 |
| Q4 2024 | +10,982 | Add 21.12% | 62,979 | $712.33 |
| Q1 2025 | +20,351 | Add 32.31% | 83,330 | $634.23 |
| Q2 2025 | -18,047 | Reduce 21.66% | 65,283 | $525.00 |
| Q3 2025 | -3,809 | Reduce 5.83% | 61,474 | $562.27 |
Jeremy Grantham's Regeneron Pharmaceuticals Investment FAQs
Jeremy Grantham first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 30,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Regeneron Pharmaceuticals, Inc. (REGN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q2 2013, adding 30,600 shares worth $6.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 61,474 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $34.56 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.10% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 83,330 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.